Type 1 diabetes is a chronic disease caused by autoimmune destruction of pancreatic
β cells. Individuals with type 1 diabetes are reliant on insulin for survival. Despite
enhanced knowledge related to the pathophysiology of the disease, including interactions
between genetic, immune, and environmental contributions, and major strides in treatment
and management, disease burden remains high. Studies aimed at blocking the immune
attack on β cells in people at risk or individuals with very early onset type 1 diabetes
show promise in preserving endogenous insulin production.